Granules India and Ajinomoto OmniChem create jv in India

Published: 18-Jul-2011
Manufacturing Ingredients Finance Pharmaceutical

Granules OmniChem will operate an API and intermediates facility in Vishakhapatnam, Andhra Pradesh

Belgian chemicals company Ajinomoto OmniChem and Indian pharmaceuticals manufacturer Granules India have formed a 50:50 joint venture to produce active pharmaceutical ingredients (APIs) and intermediates for third parties.

The new company, Granules-OmniChem, will build a US$20m plant in the Pharmacity SEZ zone in Vishakhapatnam, Andhra Pradesh, initially to manufacture high-value, low-volume APIs and intermediates.

Construction of the facility will start in November and should be completed towards the end of 2012.

The jv aims to capitalise on demand from pharmaceutical firms which are outsourcing their manufacturing needs at a time when the industry is focused on the US$234bn generics market. More than 80% of API production is for the generics market.

Granules-Omnichem will focus on producing APIs and intermediates for existing customers of both partners and in the future manufacture new chemical entities.

‘Our shareholders will benefit since this will enable Granules to diversify its business by offering high value APIs and intermediates which will increase our profitability,’ said Krishna Prasad, managing director of Granules.

Gwin Bompas, managing director of Ajinomoto OmniChem, which employs around 700 people at three sites in Belgium, said the jv would enable the firm to ‘offer access to quality medicine at an affordable price for the market’.

Granules India manufactures finished dosage forms, pharmaceutical intermediates and APIs, which are distributed in more than 50 countries.

See more

You may also like

Manufacturing

Ajinomoto Bio-Pharma Services buys out joint venture company

Read more
The purchase will transfer the remaining 50% ownership of Granules OmniChem from Ajinomoto’s joint venture partner, Granules India

Trending Articles

  1. Agility, scale and trust: the outsourcing model driving pharma forward Outsourcing in the pharmaceutical industry has long been viewed as a matter of convenience and a way to ease short-term capacity pressures or delay the decision to invest in costly new facilities. That framing no longer fits
  2. RION engages Lonza to scale manufacturing exosome based therapeutics Collaboration leverages RION’s proprietary biomanufacturing process to propel RION’s industry-leading clinical development pipeline towards late-phase trials and commercialisation for multiple regenerative medical conditions
  3. Genmab to acquire Merus in $8bn deal to expand late-stage pipeline The acquisition adds breakthrough therapy petosemtamab to Genmab’s portfolio, accelerating its shift to a wholly owned model and supporting multiple new drug launches by 2027
  4. Gerresheimer boosts Wertheim site with new production facility The new production hall will focus on RTF vials and innovative EZ-fill Smart packaging platform, with a total investment volume of around EUR €30 million
  5. Starlab launches the first TipOne racks made with recycled TipOne plastic The circle is finally complete by turning plastic lab waste back into high-quality lab products

Upcoming event

CPHI Frankfurt 2025

28–30 October 2025 | Exhibition | Frankfurt, Germany See all

You may also like

Manufacturing

Ajinomoto Bio-Pharma Services buys out joint venture company

The purchase will transfer the remaining 50% ownership of Granules OmniChem from Ajinomoto’s joint venture partner, Granules India
Finance

Indian Big Pharma companies buck the global economic trend

India\'s top 25 pharma companies continue to go from strength to strength
Manufacturing

Rentschler Biopharma expands services in Japan and South Korea ahead of BioProcess International Asia

Rentschler Biopharma will showcase its Rentschler Expression Platform and Development Services at BioProcess International Asia in Kyoto, underscoring its commitment to supporting biopharma partners across Japan and South Korea
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Decoding your personal health ecosystem: the power of microbiome diagnostics and nutraceuticals

People often talk about a “gut instinct” or a “gut feeling.” Until recently, though, actually discussing digestive health might have seemed unusual, suggests Christina Casén, Senior Vice President, Clinical and Medical Affairs at Genetic Analysis AS
Manufacturing

Navigating SOE compliance: how to strengthen organic enforcement within your organisation

Part I of NSF’s webinar series explores strategies to meet rising regulatory demands, reduce fraud, and promote ethical practices
Manufacturing

Exploring Ireland’s thriving life sciences sector

NSF highlights its pivotal role in one of the world’s leading hubs for pharma and medical device manufacturing
Manufacturing

Quality control: the central pillar supporting peptide manufacturing

Amid the growing complexity and innovation in the field, this article explores how centralised quality control plays a pivotal role by ensuring both safety and consistency during custom peptide production
Subscribe now